Dr. Richard Carvajal, MD
Claim this profileColumbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco
Studies Solid Tumors
Studies Tumors
20 reported clinical trials
60 drugs studied
About Richard Carvajal, MD
Education:
- Received MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Currently serves as the Director of Experimental Therapeutics at Columbia University Medical Center (CUIMC).
- Holds the position of Director of the Melanoma Service at CUIMC's Herbert Irving Comprehensive Cancer Center Clinical Protocols, emphasizing his focus on melanoma research.
Area of expertise
1Solid Tumors
Stage IV
Stage III
Stage II
2Tumors
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Richard Carvajal, MD is currently running
CS5001
for Advanced Cancers
This trial is testing a new drug called CS5001 to see if it is safe and effective for patients with advanced blood-related and solid cancers. The drug aims to attack and stop the growth of cancer cells.
Recruiting1 award Phase 110 criteria
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.
Recruiting1 award Phase 1 & 29 criteria
More about Richard Carvajal, MD
Clinical Trial Related2 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Richard Carvajal, MD has experience with
- Nivolumab
- Ipilimumab
- Binimetinib
- Crizotinib
- Larotrectinib
- Afatinib
Breakdown of trials Richard Carvajal, MD has run
Solid Tumors
Tumors
Melanoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard Carvajal, MD specialize in?
Richard Carvajal, MD focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Richard Carvajal, MD currently recruiting for clinical trials?
Yes, Richard Carvajal, MD is currently recruiting for 9 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Richard Carvajal, MD has studied deeply?
Yes, Richard Carvajal, MD has studied treatments such as Nivolumab, Ipilimumab, Binimetinib.
What is the best way to schedule an appointment with Richard Carvajal, MD?
Apply for one of the trials that Richard Carvajal, MD is conducting.
What is the office address of Richard Carvajal, MD?
The office of Richard Carvajal, MD is located at: Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.